AndroGel Metabolism and Energy Expenditure: What the Evidence Shows

What AndroGel Does to Resting Metabolic Rate

Testosterone directly stimulates mitochondrial biogenesis in skeletal muscle and promotes lean tissue accrual, both of which raise resting metabolic rate (RMR). In men with hypogonadism, serum testosterone below 300 ng/dL is associated with reduced skeletal muscle mass, lower mitochondrial density, and a measurably depressed RMR compared with eugonadal peers. Restoring testosterone to the 400 to 700 ng/dL range with topical gel reverses much of this deficit over months, not days.

The Lean-Mass Mechanism

Skeletal muscle is the single largest contributor to RMR, accounting for roughly 20 to 30 percent of total daily energy expenditure at rest. Testosterone binds androgen receptors in satellite cells and mature myofibers, accelerating muscle protein synthesis and inhibiting ubiquitin-proteasome-mediated protein degradation. A 2013 dose-response study (N=198) published in the Journal of Clinical Endocrinology and Metabolism found that graded testosterone doses produced graded increases in leg press strength and lean mass, with fat mass falling across all active arms compared with placebo 1. Each kilogram of added lean mass carries an estimated 50 to 80 kcal/day metabolic tax, meaning a 2 kg lean mass gain translates to roughly 100 to 160 kcal/day of additional resting caloric expenditure.

Mitochondrial and Thermogenic Pathways

Beyond simple mass, testosterone modulates mitochondrial function. Animal and human cell-culture data show testosterone upregulates PGC-1alpha expression, the master regulator of mitochondrial biogenesis, in muscle tissue 2. In men, lower free testosterone correlates with reduced VO2 max and lower fat oxidation rates during submaximal exercise, two proxies for mitochondrial capacity. A secondary analysis of the Testosterone in Older Men with Mobility Limitations (TOM) trial found that testosterone-treated men improved their stair-climbing power by 12.6 percent versus 3.9 percent in placebo at 6 months 3, consistent with genuine improvements in oxidative capacity rather than mass accrual alone.

How AndroGel Changes Body Composition

Body composition shifts are the most consistently documented metabolic outcome of testosterone gel therapy and the clearest pathway through which energy expenditure rises over time.

Fat Mass Reduction

A 2016 systematic review and meta-analysis of 58 randomized controlled trials (N=3,808) found that testosterone therapy reduced fat mass by a mean of 1.59 kg (95% CI: 2.04 to 1.13 kg, P<0.001) compared with placebo 4. Visceral adipose tissue (VAT) showed the greatest proportional reduction. VAT expresses aromatase at high levels, so testosterone-driven VAT loss also reduces peripheral estrogen conversion, a secondary metabolic benefit. The fat loss signal strengthens with treatment duration: studies shorter than 26 weeks show attenuated effects compared with 52-week trials.

Lean Mass Gains

The same 2016 meta-analysis reported a mean lean mass gain of 1.63 kg (95% CI: 1.14 to 2.13 kg, P<0.001) across testosterone arms 4. The T-Trials, a coordinated set of seven double-blind placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, confirmed this pattern: men randomized to testosterone gel (AndroGel 1%) over 12 months showed significantly greater lean mass gains than placebo in the physical-function sub-trial 5. The Endocrine Society clinical practice guideline states: "We recommend testosterone therapy for men with hypogonadism to increase lean body mass and muscle strength" 6.

The Composition Shift in Practice

Fat loss and lean gain occurring simultaneously produce a favorable shift in body composition even when total weight changes minimally. A man losing 1.6 kg of fat while gaining 1.6 kg of muscle ends a 6-month trial at approximately the same scale weight but with a meaningfully higher RMR and lower cardiometabolic risk profile. Clinicians should communicate this to patients who judge treatment success by bodyweight alone.

Testosterone Gel and Insulin Sensitivity

Insulin resistance and hypogonadism co-occur at high rates. Approximately 40 percent of men with type 2 diabetes have low testosterone, and low testosterone independently predicts incident type 2 diabetes in prospective cohorts 7.

HOMA-IR and Fasting Glucose Data

A 2011 meta-analysis (N=656, 5 RCTs) found testosterone therapy reduced HOMA-IR by a standardized mean difference of 0.43 (P<0.05) versus placebo in men with metabolic syndrome or type 2 diabetes 8. Fasting glucose fell by roughly 0.8 mmol/L (14 mg/dL) in treated men. These effects are mediated partly through increased GLUT-4 transporter expression in skeletal muscle, partly through reduced VAT and its associated adipokine-driven insulin antagonism, and partly through direct androgen receptor signaling in hepatocytes that suppresses hepatic glucose output 9.

Clinical Implications for Energy Partitioning

Improved insulin sensitivity shifts substrate partitioning away from de novo lipogenesis and toward glycogen synthesis and fat oxidation. Men on AndroGel who also adopt resistance training amplify this effect: the combination of exogenous testosterone and mechanical loading produces additive GLUT-4 upregulation, making the metabolic response greater than either intervention alone 10.

Pharmacokinetics of AndroGel and Their Metabolic Relevance

Understanding how AndroGel delivers testosterone informs why steady-state pharmacokinetics matter for metabolic outcomes.

Absorption and Steady-State Pharmacokinetics

AndroGel 1.62% applied to the upper arm or shoulder achieves peak serum testosterone (Cmax) at approximately 2 hours post-application, with a pharmacokinetic profile that stays within the eugonadal range (300 to 1,000 ng/dL) for 24 hours in most patients 11. Steady state is reached within 24 to 72 hours of daily dosing. Unlike testosterone injections, which create supraphysiologic peaks and hypogonadal troughs, daily gel application maintains a relatively flat serum concentration curve. This pharmacokinetic stability may reduce the day-to-day variability in substrate oxidation, appetite, and energy that injection cycles can create.

Conversion to Estradiol and DHT

Roughly 0.4 to 0.5 percent of applied testosterone undergoes 5-alpha reduction to dihydrotestosterone (DHT) and another 0.2 to 0.3 percent aromatizes to estradiol (E2). Estradiol at physiologic concentrations in men exerts favorable metabolic effects, including suppression of hepatic lipogenesis and improvement in endothelial insulin sensitivity 12. Excess E2 (above roughly 42 pg/mL) is associated with fluid retention and blunted fat oxidation, which is why monitoring estradiol alongside testosterone is standard practice in men on long-term gel therapy.

Inter-Individual Variability in Absorption

Skin thickness, scrotal versus non-scrotal application site, ambient temperature, and co-application of sunscreen all affect gel absorption by as much as 30 to 50 percent between individuals 13. Two men applying identical doses may achieve serum testosterone levels differing by 150 to 200 ng/dL. This variability is clinically meaningful for metabolic outcomes: men who absorb poorly and remain below 350 ng/dL will show attenuated lean mass gain and fat loss compared with adequate absorbers.

The T-Trials: Metabolic Data From the Largest Coordinated Hypogonadism Trial

The Testosterone Trials (T-Trials) represent the most rigorous clinical dataset on the effects of one year of testosterone gel therapy in older hypogonadal men.

Trial Design

The T-Trials comprised seven coordinated double-blind, placebo-controlled trials enrolling 790 men aged 65 or older with an average of two morning serum testosterone measurements below 275 ng/dL and at least one associated symptom. Participants were randomized to AndroGel 1% titrated to achieve serum testosterone of 500 ng/dL or matching placebo for 12 months. The sexual, physical, and vitality sub-trials are the most frequently cited 5.

Physical Function and Energy Expenditure

In the physical-function sub-trial (N=247), testosterone-treated men improved 6-minute walk distance by 18.8 meters versus 12.5 meters in placebo (P=0.03). Leg press strength increased by 12.9 kg in the testosterone arm versus 8.7 kg in placebo (P=0.04) 5. Greater functional capacity directly correlates with higher total daily energy expenditure because men who can walk farther and lift more actually do so in daily life, creating a positive feedback loop between testosterone therapy, activity tolerance, and caloric throughput.

Vitality and Fatigue

The vitality sub-trial found no statistically significant benefit of testosterone on PROMIS fatigue scores at 12 months, a null finding that is often underreported 5. This matters metabolically: fatigue is a primary driver of sedentary behavior, and if testosterone does not reliably reduce fatigue at population level, the activity-based route to increased energy expenditure may be less consistent than the lean-mass route.

Lipid Metabolism and Cardiovascular Metabolic Risk

Testosterone's effects on lipids are modest and directionally mixed, which makes individualized monitoring essential rather than optional.

HDL, LDL, and Triglycerides

A 2010 meta-analysis of 30 RCTs (N=1,642) found testosterone therapy produced a mean HDL reduction of 0.49 mmol/L (19 mg/dL) and a mean LDL reduction of 0.24 mmol/L (9 mg/dL) versus placebo 14. Triglycerides fell by approximately 0.24 mmol/L. The net effect on atherogenic risk depends on the patient's baseline lipid panel: men with high triglycerides and low HDL at baseline (a common pattern in metabolic syndrome and hypogonadism) tend to show a net favorable shift, while men with already-low HDL may see a clinically meaningful further reduction.

The TRAVERSE Trial Update

The 2023 TRAVERSE trial (N=5,246, mean age 63.5 years, cardiovascular risk-enriched population) found testosterone replacement therapy did not increase MACE (major adverse cardiovascular events) compared with placebo (HR 0.96, 95% CI 0.78 to 1.17) over a median follow-up of 33 months 15. TRAVERSE did, however, show a higher rate of atrial fibrillation (3.5% vs 2.4%) and pulmonary embolism (0.9% vs 0.5%) in the testosterone arm. For metabolic-focused prescribing, this means that cardiovascular risk stratification should precede any discussion of testosterone's body-composition or energy-expenditure benefits.

Practical Dosing and Monitoring for Metabolic Outcomes

Achieving metabolic benefits requires serum testosterone to actually reach the eugonadal range and stay there consistently.

Starting Dose and Titration

The FDA-approved starting dose for AndroGel 1.62% is 40.5 mg (two pump actuations) applied to the upper arms and shoulders each morning. The dose may be titrated to 20.25 mg increments (one pump actuation) based on a serum testosterone drawn 14 days after initiation or dose change, 2 to 8 hours post-application 11. The Endocrine Society 2018 guideline recommends targeting a mid-normal range testosterone of 400 to 700 ng/dL and re-checking levels at 3 months, then every 6 to 12 months once stable 6.

Monitoring Parameters With Metabolic Relevance

• Serum total testosterone: draw 2 to 8 hours after application, at 14 days and 3 months initially.
• Hematocrit: baseline, 3 months, 6 months, then annually. Hold therapy if hematocrit exceeds 54 percent 6.
• Fasting glucose and HbA1c: baseline and every 6 months in men with prediabetes or type 2 diabetes to track insulin-sensitizing response.
• Estradiol (sensitive LC-MS/MS assay): baseline and at first follow-up. Target 20 to 40 pg/mL for optimal metabolic and libido outcomes 16.
• Lipid panel: baseline and at 6 months, then annually 17.

Resistance Training as a Co-Intervention

Testosterone gel produces larger lean mass and fat loss changes when combined with structured resistance training. A 12-week RCT (N=100 hypogonadal men) found the testosterone-plus-exercise arm gained 3.1 kg lean mass versus 1.8 kg in testosterone-alone, and reduced fat mass by 2.4 kg versus 1.4 kg 18. Prescribing 2 to 3 sessions per week of progressive resistance training alongside AndroGel is not optional for men seeking maximal metabolic benefit. It is the standard of care reflected in the American College of Sports Medicine position stand on exercise in men with hypogonadism 19.

Special Populations: Obesity, Type 2 Diabetes, and Older Men

Men With Obesity (BMI >30)

Obese men have higher aromatase activity in adipose tissue, which converts more testosterone to estradiol and depresses hypothalamic-pituitary axis drive, creating functional hypogonadism. This population may require higher AndroGel doses to achieve target serum levels due to higher volume of distribution and increased conversion rates. A 2014 RCT in obese hypogonadal men (N=220) found testosterone gel over 52 weeks reduced waist circumference by 3.2 cm and HbA1c by 0.4 percent compared with lifestyle intervention alone 20.

Men With Type 2 Diabetes

The TIMES2 study (N=220, double-blind RCT) examined testosterone undecanoate in men with type 2 diabetes or metabolic syndrome. At 12 months, HOMA-IR decreased by 15.2 percent in testosterone versus an increase of 2.3 percent in placebo (P=0.02) 21. While TIMES2 used injections rather than gel, the androgen receptor mechanisms are identical. Gel-based therapy in this population should include quarterly HbA1c monitoring given the potential need for antidiabetic medication dose adjustment as insulin sensitivity improves.

Men Aged 65 and Older

Older men show attenuated anabolic responses to testosterone compared with younger hypogonadal men, partly due to age-related reductions in satellite cell number and growth hormone co-signaling. The T-Trials confirmed lean mass gains are achievable even at age 65 to 80, but the absolute magnitude is smaller 5. Estradiol monitoring is especially relevant in this group because bone protection in older men depends significantly on estradiol levels staying above 20 pg/mL 22.